Breaking News Instant updates and real-time market news.

KURA

Kura Oncology

$18.85

(0.00%)

11:04
02/15/18
02/15
11:04
02/15/18
11:04

Kura provides update on Phase 2 Tipifarnib trial

Kura Oncology announced the presentation of updated preliminary results from its Phase 2 clinical trial of its lead product candidate, tipifarnib, in patients with head and neck squamous cell carcinomas with HRAS mutations. The results are being presented by Alan Ho, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center at the 2018 Multidisciplinary Head and Neck Cancers Symposium, taking place today in Scottsdale, Arizona. Nine patients with HRAS mutant HNSCC had been enrolled in the Phase 2 trial as of the February 8, 2018 data cutoff date. Five out of the six evaluable patients achieved a confirmed, partial response as defined by standard RECIST criteria for an overall response rate of 83%, including durable responses of more than 18 months in two patients. The sixth evaluable patient experienced tumor shrinkage and prolonged disease stabilization. Three additional patients were enrolled since the last update in October 2017, however, none of the three additional patients was evaluable as of the February 8th data cutoff date; two are off study and one was still too early for disease assessment. All patients joined the trial upon progression from at least one line of therapy, including chemotherapy, cetuximab or immune therapy, with patients having experienced a median of two prior therapies. Response rates for the three agents approved for treatment of HNSCC in the second line are in the range of 13-16%, with a median progression-free survival of approximately 2 months and a median overall survival of up to 7.5 months. Tipifarnib was generally well-tolerated in the trial. Adverse events observed are consistent with the known safety profile of tipifarnib. In September 2017, Kura announced that the Phase 2 trial in HRAS mutant HNSCC had achieved its primary efficacy endpoint prior to the completion of enrollment. The trial protocol required four confirmed, partial responses, per RECIST 1.1 criteria, out of 18 patients to meet its primary endpoint.

  • 15

    Feb

KURA Kura Oncology
$18.85

(0.00%)

08/08/17
SBSH
08/08/17
NO CHANGE
Target $13
SBSH
Buy
Kura Oncology Phase 2 trial update 'encouraging,' says Citi
Citi analyst Joel Beatty views Kura Oncology's Phase 2 HRAS mutant SCCHN trial update as "encouraging." Though the number of patients is still small, the 60% partial response rate is higher than the 13%-16% rate seen historically with approved agents in the squamous cell carcinomas of the head and neck setting, Beatty tells investors in a research note. He raised his price target for Kura shares to $13 from $12 and keeps a Buy rating on the name.
09/07/17
COWN
09/07/17
INITIATION
COWN
Outperform
Kura Oncology initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Kura Oncology with an Outperform saying its uniquely positioned to generate significant value from its precision based approach to developing its lead compound, tipifarnib. The analyst said recent clinical data increases confidence in tipifarnib's opportunity in HRAS-mutan SCCHN, with additional opportunity in PTCL. Shibutani sees a commercial peak sales of $600M+ for these orphan oncology indications.
11/09/17
SBSH
11/09/17
NO CHANGE
Target $19
SBSH
Buy
Kura Oncology price target raised to $19 from $15 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $19 ahead of next week's investor meeting and keeps a Buy rating on the shares. The analyst believes the data to date for Tipifarnib in HRAS-mutant head and neck squamous cell carcinoma suggests it could be superior to the 13%-16% response rate typically seen with the standard of care.
12/20/17
WEDB
12/20/17
INITIATION
Target $19
WEDB
Outperform
Kura Oncology initiated with an Outperform at Wedbush
Wedbush initiated Kura Oncology with an Outperform and $19 price target.

TODAY'S FREE FLY STORIES

YVR

Liquid Media

$3.57

0.02 (0.56%)

10:06
03/25/19
03/25
10:06
03/25/19
10:06
Hot Stocks
Liquid Media executes agreement to acquire Open Nuage for $858,750 »

Liquid Media Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$23.55

0.22 (0.94%)

10:05
03/25/19
03/25
10:05
03/25/19
10:05
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$100.77

-0.61 (-0.60%)

10:04
03/25/19
03/25
10:04
03/25/19
10:04
Periodicals
Venmo threatens users with debt collectors in effort to curb losses, WSJ reports »

PayPal's digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFRA

Biofrontera

$11.88

(0.00%)

10:04
03/25/19
03/25
10:04
03/25/19
10:04
Hot Stocks
Biofrontera acquires Cutanea Life Sciences, Inc., USA »

Biofrontera Inc., USA, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMSC

AMSC

$12.00

-0.16 (-1.32%)

10:02
03/25/19
03/25
10:02
03/25/19
10:02
Hot Stocks
AMSC mentioned cautiously in a Seeking Alpha article 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BE

Bloom Energy

$11.11

-0.69 (-5.85%)

10:00
03/25/19
03/25
10:00
03/25/19
10:00
Hot Stocks
Bloom Energy falls -6.2% »

Bloom Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

NUS

Nu Skin

$45.70

-3.65 (-7.40%)

10:00
03/25/19
03/25
10:00
03/25/19
10:00
Hot Stocks
Nu Skin falls -7.0% »

Nu Skin is down -7.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEG

Key Energy

$4.39

-0.41 (-8.54%)

10:00
03/25/19
03/25
10:00
03/25/19
10:00
Hot Stocks
Key Energy falls -8.1% »

Key Energy is down -8.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

YRD

Yirendai

$11.94

0.49 (4.28%)

10:00
03/25/19
03/25
10:00
03/25/19
10:00
Hot Stocks
Yirendai rises 5.1% »

Yirendai is up 5.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

AVYA

Avaya

$17.60

4.37 (33.03%)

10:00
03/25/19
03/25
10:00
03/25/19
10:00
Hot Stocks
Avaya rises 33.2% »

Avaya is up 33.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIER

Tier REIT

$28.00

2.49 (9.76%)

10:00
03/25/19
03/25
10:00
03/25/19
10:00
Hot Stocks
Tier REIT rises 9.6% »

Tier REIT is up 9.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TSLA

Tesla

$257.95

-6.63 (-2.51%)

09:57
03/25/19
03/25
09:57
03/25/19
09:57
Options
Tesla implied volatility surges as shares slip to 5 month lows »

Tesla implied volatility…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$50.35

-0.4 (-0.79%)

09:55
03/25/19
03/25
09:55
03/25/19
09:55
Options
TripAdvisor put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$27.21

1.94 (7.68%)

, TGNA

Tegna

$14.16

0.35 (2.53%)

09:55
03/25/19
03/25
09:55
03/25/19
09:55
Options
Early notable gainers among liquid option names on March 25th »

Notable gainers among…

VIAB

Viacom

$27.21

1.94 (7.68%)

TGNA

Tegna

$14.16

0.35 (2.53%)

JWN

Nordstrom

$43.53

0.61 (1.42%)

M

Macy's

$23.70

0.37 (1.59%)

ORLY

O'Reilly Automotive

$381.18

5.14 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

ANAB

AnaptysBio

$70.38

-0.85 (-1.19%)

09:55
03/25/19
03/25
09:55
03/25/19
09:55
Conference/Events
AnaptysBio participates in a conference call with JPMorgan »

SMid Biotech Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

09:50
03/25/19
03/25
09:50
03/25/19
09:50
General news
One smoking gun for the Fed's market liquidity concerns »

One smoking gun for the…

NUS

Nu Skin

$49.35

(0.00%)

09:47
03/25/19
03/25
09:47
03/25/19
09:47
Hot Stocks
Nu Skin falls -4.8% »

Nu Skin is down -4.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$3.76

(0.00%)

09:47
03/25/19
03/25
09:47
03/25/19
09:47
Hot Stocks
Cellcom Israel falls -5.1% »

Cellcom Israel is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCM

Cheetah Mobile

$6.25

-0.69 (-9.94%)

09:47
03/25/19
03/25
09:47
03/25/19
09:47
Hot Stocks
Cheetah Mobile falls -7.7% »

Cheetah Mobile is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TCI

Transcontinental Realty Inc

$31.23

-6.48 (-17.18%)

09:47
03/25/19
03/25
09:47
03/25/19
09:47
Hot Stocks
Transcontinental Realty Inc rises 5.0% »

Transcontinental Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIER

Tier REIT

$27.74

2.23 (8.74%)

09:47
03/25/19
03/25
09:47
03/25/19
09:47
Hot Stocks
Tier REIT rises 8.4% »

Tier REIT is up 8.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

AVYA

Avaya

$17.74

4.51 (34.09%)

09:47
03/25/19
03/25
09:47
03/25/19
09:47
Hot Stocks
Avaya rises 34.1% »

Avaya is up 34.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

Lululemon

$142.50

-1.34 (-0.93%)

09:46
03/25/19
03/25
09:46
03/25/19
09:46
Recommendations
Lululemon analyst commentary  »

MKM lowers Lululemon Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

AGCO

Agco

$67.65

0.27 (0.40%)

09:45
03/25/19
03/25
09:45
03/25/19
09:45
Recommendations
Agco analyst commentary  »

Agco price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

D

Dominion

$75.51

(0.00%)

09:44
03/25/19
03/25
09:44
03/25/19
09:44
Conference/Events
Dominion to host investor day »

Sustainability and ESG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 25

    Mar

  • 07

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.